Small interfering RNA (siRNA) with 19–21 base pairs has been recently recognized as a new therapeutic agent for effectively silencing a specific gene on a post-transcription level. For siRNA ...
When performing RNAi experiments using siRNAduplexes, the first critical challenge is the design ofefficient siRNA. Recent studies concerning the importanceof mRNA accessibility in relation to the ...
PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent ...
QPI-1002 is undergoing trials for prevention of acute kidney injury and delayed graft function. Novartis is paying Quark Pharmaceuticals $10 million for an option to obtain exclusive worldwide rights ...
RNA interference (RNAi) is a biological process that inhibits the expression of target genes in the cells of animals, plants, and fungi, and hence, researchers call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback